Kidney Cancer Diagnostics And Therapeutics Market Report 2026

Kidney Cancer Diagnostics And Therapeutics Market Overview

• Kidney Cancer Diagnostics And Therapeutics market size has reached to $4.31 billion in 2025 • Expected to grow to $6.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rise In Prevalence Of Kidney Cancer Drives Growth In The Diagnostics And Therapeutics Market • Market Trend: Advancements In Kidney Cancer Diagnostics And Therapeutics Focus On Renal Cell Carcinoma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kidney Cancer Diagnostics And Therapeutics Market?

Kidney cancer diagnostics and therapeutics refer to a process of methods and treatments used for diagnosing and managing kidney cancer, also known as renal cell carcinoma. These approaches aim to detect the presence of kidney cancer, determine its stage and extent, and provide appropriate treatment options to manage the disease. The main types of cancer are clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma and transitional cell carcinoma, and others. Clear-cell renal cell carcinoma (RCC) refers to a type of kidney cancer that accounts for the majority of all kidney cancer cases. RCC is further classified into different subtypes based on the appearance of cancer cells under a microscope. Kidney cancer diagnostics and therapeutics offer significant benefits in the management of clear cell renal cell carcinoma (RCC), which is the most common subtype of kidney cancer. These are treated by using components such as drugs and diagnostics. These are diagnosed by using several types of diagnostics such as biopsy, CT scan, nephro-ureteroscopy, intravenous pyelogram and ultrasound and treated by therapies including targeted therapy, immunotherapy, and chemotherapy. The main end-users are hospitals, pharmaceutical labs, and genomic laboratories.

What Is The Kidney Cancer Diagnostics And Therapeutics Market Growth Forecast?

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rising adoption of immunotherapy regimens, increasing investment in oncology research, growing use of genomic testing in cancer care, expansion of precision medicine approaches, improving access to advanced cancer diagnostics. Major trends in the forecast period include rising adoption of targeted and immunotherapy treatments, increasing use of advanced imaging for early diagnosis, growing demand for personalized kidney cancer treatment, expansion of biomarker-based diagnostic approaches, improved integration of diagnostics and therapeutics.

Global Kidney Cancer Diagnostics And Therapeutics Market Segmentation

1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma 2) By Component: Drugs, Diagnostics 3) By Therapy: Targeted Therapy, Immunotherapy 4) By End-Users: Hospitals, Genomics Laboratories Subsegments: 1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV 2) By Papillary RCC: Type 1, Type 2 3) By Chromophobe RCC: Localized, Advanced 4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-Muscle Invasive, Muscle Invasive, Metastatic

What Is The Driver Of The Kidney Cancer Diagnostics And Therapeutics Market?

The increasing prevalence of kidney cancer is expected to drive the growth of kidney cancer diagnostics and therapeutics market. Kidney cancer refers to a condition that originates when the normal cells in one or both kidneys undergo abnormal changes and exhibit uncontrolled growth, resulting in the formation of a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer play a crucial role in the management and treatment of the disease, offering several benefits for patients. offer several benefits in the management of kidney cancer, such as early detection, accurate diagnosis, treatment selection, personalized medicine, and treatment monitoring. For instance, in May 2024, according to the American Cancer Society, a US-based nonprofit cancer research and advocacy organization, an estimated 81,610 new cases of kidney cancer were expected to be diagnosed in 2024, along with 14,390 projected deaths. Therefore, the increasing prevalence of kidney cancer is expected to propel the growth of kidney cancer diagnostics and therapeutics industry.

Key Players In The Global Kidney Cancer Diagnostics And Therapeutics Market

Major companies operating in the kidney cancer diagnostics and therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co., Ltd., Ipsen S.A., Exelixis Inc., Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Invitae Corporation, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings

Global Kidney Cancer Diagnostics And Therapeutics Market Trends and Insights

Major companies operating in kidney cancer diagnostics and therapeutics market are focusing on developing advanced renal cell carcinoma (RCC) to improve patient outcomes and provide innovative treatment options tailored to the specific needs of individuals diagnosed with this challenging disease. Research into renal cell carcinoma (RCC) is essential for kidney cancer diagnostics and therapeutics, as it drives the creation of innovative diagnostic methods and targeted therapies that improve early diagnosis and individualized treatment for patients. For instance, in December 2023, Merck, a US-based pharmaceutical company, launched welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) after prior treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This novel therapeutic class shows significant benefits, including improved progression-free survival and higher response rates compared to everolimus. WELIREG's approval represents a crucial advancement in the kidney cancer diagnostics and therapeutics market, offering new hope for patients with progressing disease.

What Are Latest Mergers And Acquisitions In The Kidney Cancer Diagnostics And Therapeutics Market?

In May 2023, Telix Pharmaceuticals Limited, an Australia-based biotechnology research company, acquired QSAM Biosciences, Inc. for an undisclosed amount. This acquisition aims to enhance Telix's portfolio in the development of targeted radiopharmaceuticals, particularly for cancer treatment. By integrating QSAM's expertise and technologies, Telix seeks to accelerate the advancement of its innovative therapies and expand its market presence in the field of precision medicine. QSAM Biosciences Inc. is a US-based biotechnology research company.

Regional Outlook

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Kidney Cancer Diagnostics And Therapeutics Market?

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kidney Cancer Diagnostics And Therapeutics Market Report 2026?

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.